Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 2651–2700 of 18616
On February 10, 2025, Sadot Group Inc. (the “Company”) appointed Catia Jorge as the Chief Executive Officer, effective February 10, 2025.
John Witek will resign from his position as Interim Chief Financial Officer of the Company.
the Board of Directors of the Company (the “Board”) has appointed Bob Gold as the Company’s Executive Vice President and Chief Financial Officer, effective as of March 10, 2025.
AJ Lee, Interim Chief Executive Officer and Chief Operating Officer, will step down as the Company’s Interim Chief Executive Officer and Chief Operating Officer, effective February 14, 2025.
Patricia Huerta will serve as acting Chief Executive Officer in addition to the Company’s Interim Chief Financial Officer.
On February 12, 2025, the Board of Directors (the “ Board ”) of Paycom Software, Inc. (the “ Company ”) appointed Bob Foster to serve as Chief Financial Officer of the Company, effective immediately following Craig Boelte’s retirement on February 21, 2025.
Mr. Boelte notified the Board on July 31, 2024 that he intended to retire from his role as Chief Financial Officer within nine to 12 months.
On February 11, 2025, Mark Iwicki notified KALA BIO, Inc. (the “Company”) of his decision to resign as the Chief Executive Officer of the Company, effective immediately.
On February 11, 2025, the Board appointed Todd Bazemore as the interim Chief Executive Officer and principal executive officer of the Company, effective immediately.
In addition, effective as of the Company Merger Effective Time, Stuart A. Tanz (Chief Executive Officer), Michael B. Haines (Chief Financial Officer) and Richard K. Schoebel (Chief Operating Officer) ceased to be officers of the Company and their employment with the Company terminated.
In addition, effective as of the Company Merger Effective Time, Stuart A. Tanz (Chief Executive Officer), Michael B. Haines (Chief Financial Officer) and Richard K. Schoebel (Chief Operating Officer) ceased to be officers of the Company and their employment with the Company terminated.
On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a Nuvation Bio Inc. (the “Company”) company, departed the Company following the achievement of key Company goals
On January 22, 2025, Jun Liu resigned from his position as the Chief Executive Officer, director and Chairman of the board of directors (the “ Board ”) of ATIF Holdings Limited, (the “ Company ”), effective immediately.
Effective January 22, 2025, the Board appointed Dr. Kamran Khan as the Chief Executive Officer of the Company, director and Chairman of the Board, to fill the vacancy created by the resignation of Jun Liu.
Effective February 11, 2025, American Coastal Insurance Corporation's ("ACIC") Board of Directors appointed B. Bradford Martz, age 53, as Chief Executive Officer and President of ACIC.
On February 11, 2025, Craig J. Demarest, the Chief Financial Officer and principal financial and accounting officer of Crown Crafts, Inc., notified the Company’s Board of Directors (the “Board”) of his decision to retire from all positions he holds with the Company and its subsidiaries, effective June 30, 2025.
Mr. Coblentz will continue in his CFO and CAO roles until March 28th to support a smooth transition to Casey Mueller, the Company’s Principal Accounting Officer and Global Controller, who, following Mr. Coblentz’s departure will serve as interim CFO.
On February 7, 2025, Mr. Jonathan Coblentz notified the Company that effective March 28, 2025, he plans to retire from his role as Chief Financial Officer (“CFO”) and Chief Administrative Officer (“CAO”) of the Company.
On February 7, 2025, Julius Ivancsits resigned as Chief Financial Officer of Splash Beverage Group, Inc.
On February 11, 2025, we announced that Joseph A. Ferraro, President and Chief Executive Officer, will transition to a Board Advisor role effective June 30, 2025.
the Board of Directors (the "Board") of the Company appointed Brian J. Choi, who has been serving as Chief Transformation Officer, as the Company's Chief Executive Officer ("CEO"), effective July 1, 2025.
On February 10, 2025, the Board elected Charles Smotherman, the Company's Senior Vice President, Chief Accounting Officer, as the Company's interim Chief Financial Officer, effective as of March 24, 2025
On February 7, 2025, Claire Bramley notified the Company of her decision to resign from her position as Chief Financial Officer of the Company (including as its principal financial officer and principal accounting officer) to take a Chief Financial Officer position with another company that is outside of the Company's industry.
Mr. Braunstein ceased to be President and Chief Executive Officer of the Company
Anders Edvell was appointed President and Chief Executive Officer of the Company
after which date Mr. Walker has been appointed and will begin serving as President and Chief Executive Officer of the Company
the previously reported retirement of Gregory S. Bielli, who has served in this capacity with the Company since December 2013.
Effective February 11, 2025, Vineet Agarwal, Chief Financial Officer (principal financial officer and principal accounting officer) of Korro Bio, Inc., or Korro, is taking a temporary medical leave of absence.
Korro’s Board of Directors appointed Dr. Ram Aiyar, President and Chief Executive Officer (principal executive officer), to serve as Korro’s interim principal financial officer
on February 5, 2025, the Company and Mr. Mattacchione agreed to extend the effective date of Mr. Mattacchione’s resignation to February 20, 2025
In connection with Ms. Chaibi’s appointment, Richard B. Leeds resigned as the Company’s Interim Chief Executive Officer, effective as of the Effective Date.
On February 10, 2025, Global Industrial Company (the “Company”) announced the appointment of Anesa Chaibi as Chief Executive Officer (principal executive officer) of the Company, effective February 17, 2025 (the “Effective Date”).
the Board of Directors elected Mr. Eric A. Clark to succeed Mr. Eddie Capel as President and Chief Executive Officer of the Company, to be effective February 12, 2025.
On February 10, 2025, the Board of Directors (the “Board”) of IDEAYA Biosciences, Inc. (the “Company”) appointed Joshua Bleharski, Ph.D. as Chief Financial Officer of the Company, effective early May 2025
Ms. Romo will step down from that role
unanimously elected Tom Doxey to succeed Tammy Romo as Executive Vice President & Chief Financial Officer
On February 10, 2025, the Company announced the appointment of Lorenzo A. Flores as Senior Vice President, Chief Financial Officer (“CFO”) of the Company, effective February 10, 2025
On February 10, 2025, the Company terminated the employment of each of Jeffrey M. Soinski, the Company’s Chief Executive Officer and Nabeel Subainati, Vice President, Finance, effective as of February 10, 2025.
the Board appointed following officers and directors: Adam Clode, Chief Executive Officer
On February 3, 2025, Balu Balakrishnan notified the Company that he intends to retire from his position as president and chief executive officer.
On February 5, 2025 (the “Termination Date”), Mark Guerin resigned from his position as the Chief Financial Officer of Traws Pharma, Inc.
On February 5, 2025, the Company’s Board of Directors appointed Nora Brennan as the Company’s Interim Chief Financial Officer.
Erin Day, 41, the Company’s Executive Vice President of Finance, will be acting Chief Financial Officer effective immediately.
Daniel J. Mathewes, President and Chief Financial Officer of Hilton Grand Vacations Inc. (the “Company”), informed the Company that he is taking a temporary leave of absence from his position at the Company for personal reasons, effective immediately.
Garett Rosenblum 51 Chief Financial Officer and Treasurer
Darren L. Richman is the Chief Executive Officer and President of Millrose.
approved the appointment of Mr. Blair Jordan as Chief Executive Officer of the Company (previously Mr. Jordan was Interim Chief Executive Officer of the Company)
On February 3, 2025, the Board appointed Farouq Tuweiq (“ Mr. Tuweiq ”) as the successor President and CEO of the Company, effective immediately following the 2025 Annual Meeting.
In light of Mr. Tuweiq’s upcoming elevation to the President and CEO role, it is anticipated that Mr. Tuweiq will vacate his current role as CFO / PFO concurrently with his assumption of the CEO role effective immediately following the 2025 Annual Meeting, with the Board having initiated a search process to identify a successor CFO / PFO for the Company.
On February 3, 2025, Michael S. Abrams, Chief Financial Officer and Treasurer of Arch Therapeutics, Inc. (the “Company”), resigned from his positions with the Company, effective immediately, and has waived any potential rights or claim to any financial obligations under his employment contract.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.